Expression of Immunoglobulin-like Transcript (ILT)2 and ILT3 in Human Gastric Cancer and Its Clinical Significance

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2012 Jan 17

PMID 22246571

Citations 24

Authors

Yi Zhang

Nan Lu

Yuwen Xue

Min Zhang

Yingjie Li

Yuanquan Si

Xiaokun Bian

Yanfei Jia

Yunshan Wang

Affiliations

Soon will be listed here.

Abstract

Immune inhibitory receptors play an important role in organ transplantation, autoimmune diseases and cancers. Immunoglobulin-like transcript (ILT)2 and ILT3 belong to the inhibitory receptors of the ILT family, which have been reported to regulate a broad range of cellular functions involved in the immune response. They contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which are related to immune regulation. Although ILT receptors have been studied in dendritic cells (DCs), T cells, NK cells and other cell types, the expression and clinical significance of ILT2 and ILT3 in gastric cancer have yet to be elucidated. Here, the expression of ILT2 and ILT3 in gastric cancer cell lines and pathologic tissues, as well as their effects on the cytotoxicity of NK92MI against the gastric cancer cell lines MKNI with ILT2lowILT3low and HGC-27 with ILT2highILT3high were detected. The results suggest that ILT2 and ILT3 are expressed with diverse degrees in gastric cancer cells and tissues, and the expression of ILT2 is related with differentiation and size of tumors. Furthermore, the cytotoxic activity of NK92MI against the MKNI cell line was stronger than that against HGC-27. This study indicates that ILT2 and ILT3 play a key role in gastric cancer immune escape, and ILT2 may be a new target in the clinical diagnosis and treatment of gastric cancer.

Citing Articles

Leukocyte immunoglobulin-like receptor B4 (LILRB4) in acute myeloid leukemia: From prognostic biomarker to immunotherapeutic target.

Li M, Zhao X Chin Med J (Engl). 2024; 137(22):2697-2711.

PMID: 38973293 PMC: 11611246. DOI: 10.1097/CM9.0000000000003195.

Analysis of HLA-G 14 bp Insertion/Deletion Polymorphism and HLA-G, ILT2 and ILT4 Expression in Head and Neck Squamous Cell Carcinoma Patients.

Durmanova V, Tedla M, Rada D, Bandzuchova H, Kuba D, Suchankova M Diseases. 2024; 12(2).

PMID: 38391781 PMC: 10888050. DOI: 10.3390/diseases12020034.

Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting.

Crimini E, Boscolo Bielo L, Berton Giachetti P, Pellizzari G, Antonarelli G, Taurelli Salimbeni B Cancers (Basel). 2024; 16(2).

PMID: 38254772 PMC: 10813411. DOI: 10.3390/cancers16020281.

Human leukocyte immunoglobulin-like receptors in health and disease.

Redondo-Garcia S, Barritt C, Papagregoriou C, Yeboah M, Frendeus B, Cragg M Front Immunol. 2023; 14:1282874.

PMID: 38022598 PMC: 10679719. DOI: 10.3389/fimmu.2023.1282874.

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.

Zeller T, Munnich I, Windisch R, Hilger P, Schewe D, Humpe A Front Immunol. 2023; 14:1240275.

PMID: 37781391 PMC: 10533923. DOI: 10.3389/fimmu.2023.1240275.

References

Gleissner C, Dengler T . Induction of ILT expression on nonprofessional antigen presenting cells: Clinical applications. Hum Immunol. 2009; 70(5):357-9. DOI: 10.1016/j.humimm.2009.01.025. View

Chui C, Li D . Role of immunolglobulin-like transcript family receptors and their ligands in suppressor T-cell-induced dendritic cell tolerization. Hum Immunol. 2009; 70(9):686-91. DOI: 10.1016/j.humimm.2009.06.003. View

Favier B, LeMaoult J, Lesport E, Carosella E . ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J. 2009; 24(3):689-99. DOI: 10.1096/fj.09-135194. View

Chen Y, Chu F, Gao F, Zhou B, Gao G . Stability engineering, biophysical, and biological characterization of the myeloid activating receptor immunoglobulin-like transcript 1 (ILT1/LIR-7/LILRA2). Protein Expr Purif. 2007; 56(2):253-60. DOI: 10.1016/j.pep.2007.08.010. View

Pilsbury L, Allen R, Vordermeier M . Modulation of Toll-like receptor activity by leukocyte Ig-like receptors and their effects during bacterial infection. Mediators Inflamm. 2010; 2010:536478. PMC: 2903975. DOI: 10.1155/2010/536478. View

Hirokawa K, Utsuyama M, Ishikawa T, Kikuchi Y, Kitagawa M, Fujii Y . Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mech Ageing Dev. 2008; 130(1-2):86-91. DOI: 10.1016/j.mad.2008.05.001. View

Morel E, Bellon T . Amoxicillin conjugates to HLA class I molecules and interferes with signalling through the ILT2/LIR-1/CD85j inhibitory receptor. Allergy. 2007; 62(2):190-6. DOI: 10.1111/j.1398-9995.2006.01285.x. View

Brown D, Jones D, Anderson K, Lapaque N, Buerki R, Trowsdale J . The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection. BMC Immunol. 2009; 10:56. PMC: 2773765. DOI: 10.1186/1471-2172-10-56. View

Vlad G, King J, Chang C, Liu Z, Friedman R, Torkamani A . Gene profile analysis of CD8(+) ILT3-Fc induced T suppressor cells. Hum Immunol. 2010; 72(2):107-14. DOI: 10.1016/j.humimm.2010.10.012. View

10.

Suciu-Foca N, Cortesini R . Central role of ILT3 in the T suppressor cell cascade. Cell Immunol. 2007; 248(1):59-67. DOI: 10.1016/j.cellimm.2007.01.013. View

11.

Wu J, Horuzsko A . Expression and function of immunoglobulin-like transcripts on tolerogenic dendritic cells. Hum Immunol. 2009; 70(5):353-6. PMC: 2775504. DOI: 10.1016/j.humimm.2009.01.024. View

12.

Cella M, Dohring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A . A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med. 1997; 185(10):1743-51. PMC: 2196312. DOI: 10.1084/jem.185.10.1743. View

13.

Kim-Schulze S, Seki T, Vlad G, Scotto L, Fan J, Colombo P . Regulation of ILT3 gene expression by processing of precursor transcripts in human endothelial cells. Am J Transplant. 2006; 6(1):76-82. DOI: 10.1111/j.1600-6143.2005.01162.x. View

14.

Taams L, van Amelsfort J, Tiemessen M, Jacobs K, de Jong E, Akbar A . Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol. 2005; 66(3):222-30. PMC: 3904343. DOI: 10.1016/j.humimm.2004.12.006. View

15.

Petty J, He K, Corless C, Vetto J, Weinberg A . Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg. 2002; 183(5):512-8. DOI: 10.1016/s0002-9610(02)00831-0. View

16.

Banham A, Colonna M, Cella M, Micklem K, Pulford K, Willis A . Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. J Leukoc Biol. 1999; 65(6):841-5. DOI: 10.1002/jlb.65.6.841. View

17.

Colonna M, Nakajima H, Cella M . A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Semin Immunol. 2000; 12(2):121-7. DOI: 10.1006/smim.2000.0214. View

18.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

19.

Xu X, Zou P, Chen L, Jin G, Zhou H . IL-10 enhances promoter activity of ILT4 gene and up-regulates its expression in THP-1 cells. J Huazhong Univ Sci Technolog Med Sci. 2010; 30(5):594-8. DOI: 10.1007/s11596-010-0548-8. View

20.

Nakajima H, Samaridis J, Angman L, Colonna M . Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain. J Immunol. 1999; 162(1):5-8. View